-
UT Southwestern partners with Pfizer on RNA delivery tech
Dallas-based UT Southwestern Medical Center is partnering with Pfizer to develop RNA-enhanced delivery technologies for genetic medicine therapies. -
2M lab devices flagged for testing issue
More than 2 million 2,363,168 products BD Sensi-Disc products cannot be used for Haemophilus influenzae testing, a Becton Dickinson spokesperson told Becker's. -
CDC seeks to expand U of Michigan's hypertension pharmacy program model
The University of Michigan in Ann Arbor has piloted a program aimed at involving pharmacists as part of the care team for patients with hypertension. Its success has prompted the CDC to begin scaling the model for wider use. -
This cancer drug could treat Parkinson's
A chemotherapy drug could potentially be a treatment for Parkinson's disease, a recent study found. -
Gyms, nutrition startups race to combat Ozempic muscle loss
A growing number of companies ranging from gyms to meal delivery services are launching new offerings to capitalize on a known issue that can happen for patients on weight loss drugs such as Ozempic and Wegovy, The New York Times reported Feb. 8. -
Ohio fines 1 CVS store $250K for understaffing
Ohio's Board of Pharmacy handed a CVS pharmacy a $250,000 fine and probation for at least three years following a 2021 investigation that found understaffing, a broken air conditioning unit, unsafe storage for medications and other issues. -
If FDA swipes common decongestant, supply issues expected
If the FDA removes the approval of phenylephrine, a common ingredient used in decongestants that research shows is ineffective, a new study says supply chain disruptions are likely. -
Aspiring pharmacist union slams CVS' $2B earnings
A day after CVS Health reported earning $2 billion in its fourth quarter of 2023, the Pharmacy Guild — an aspiring union of retail pharmacists — criticized the company, saying CVS' profits are from "chronic understaffing." -
HHS to pharmacies: Ensure patients aren't overcharged for Paxlovid
In a Feb. 5 meeting with retail pharmacy CEOs, HHS Secretary Xavier Becerra stressed that patients should not be paying the full list price or high copays for Pfizer's Paxlovid drug. -
Weight loss drugs tied to fewer anxiety, depression cases: Study
Patients who take Ozempic, Mounjaro and Wegovy are less likely to be diagnosed with anxiety or depression compared to those who don't receive the popular diabetes and weight loss drugs, according to a new study. -
Mercy hospital to move pharmacy, add oncology services
Cincinnati-based Mercy Health is moving its Urbana (Ohio) Hospital's pharmacy from a small hallway space near the emergency department to its own space in 2024. -
Prevent drug shortages, save hospitals $550M: AHA
Drug shortages inflict more than $550 million in additional costs every year on hospitals and health systems, the American Hospital Association said in a letter to Congress. -
Automation delivers much-needed relief to a strained healthcare workforce
Hospitals and health systems are currently experiencing what many consider to be a labor crisis – particularly among caregivers. -
Newly acquired Novo Nordisk plant struggles to meet quality standards, FDA finds
Last fall, FDA inspectors found multiple safety and quality issues at one of the manufacturing sites Novo Nordisk has agreed to purchase, according to a Feb. 6 Bloomberg report. -
Zepbound, Mounjaro show potential for fatty liver disease
Eli Lilly's phase 2 study of Mounjaro and Zepbound found promising results for the medications to treat fatty liver disease, the drugmaker said Feb. 6. -
FDA to consider RSV vaccine for adults in their 50s
Respiratory syncytial virus vaccinations could soon extend to adults aged 50-59. -
5 Ozempic updates
In 2024, the cost of Ozempic increased 3.5% as health systems, payers and patients scramble to manage the drug's soaring popularity. -
Zepbound may significantly lower blood pressure in overweight adults, new study finds
Eli Lilly's ingredient for Type 2 diabetes medication Mounjaro and its new weight loss drug, Zepbound, significantly lowered patients' blood pressure by up to 10.6 mmHg, according to a new study published Feb. 5. -
Walgreens, pharmacy schools to boost talent pipeline
Walgreens has formed a new advisory council with pharmacy school leaders to address staffing challenges and fortify the pipeline of future pharmacists. -
Novo Nordisk to buy 3 fill-finish sites in $11B deal
As Novo Nordisk increases the output of its popular weight loss drug Wegovy, the Denmark-based drugmaker agreed to buy three fill-finish manufacturing sites for $11 billion.
Page 29 of 50